Selected article for: "ace receptor receptor and acute respiratory syndrome"
Author: Ventura, Davide; Carr, Amy L; Davis, R Duane; Silvestry, Scott; Bogar, Linda; Raval, Nirav; Gries, Cynthia; Hayes, Jillian E; Oliveira, Eduardo; Sniffen, Jason; Allison, Steven L; Herrera, Victor; Jennings, Douglas L; Page, Robert L; McDyer, John F; Ensor, Christopher R
Title: Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury
  • Cord-id: j0gi07wj
  • Document date: 2021_4_4
    • ID: j0gi07wj
    Snippet: It has been established SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2), a membrane-bound regulatory peptide, for host cell entry. Renin-angiotensin-aldosterone system (RAAS) inhibitors have been reported to increase ACE2 in type 2 pneumocytes pulmonary tissue. Controversy exists for the continuation of ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) in the current pandemic. ACE2 serves as regulatory enzyme in maintaining homeosta
    Document: It has been established SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2), a membrane-bound regulatory peptide, for host cell entry. Renin-angiotensin-aldosterone system (RAAS) inhibitors have been reported to increase ACE2 in type 2 pneumocytes pulmonary tissue. Controversy exists for the continuation of ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) in the current pandemic. ACE2 serves as regulatory enzyme in maintaining homeostasis between proinflammatory Angiotensin II and anti-inflammatory Angiotensin 1,7 peptides. Derangements in these peptides are associated with cardiovascular disease and are implicated in the progression of acute respiratory distress syndrome (ARDS). Augmentation of the ACE2/Ang1,7 axis represent a critical target in the supportive management of COVID-19 associated lung disease. Observational data describing the use of RAAS inhibitors in the setting of SARS-CoV-2 have not borne signals of harm to date. However, equipoise persists requiring an analysis of novel agents including recombinant human-ACE2 and existing RAAS inhibitors while balancing ongoing controversies associated with increased coronavirus infectivity and virulence.

    Search related documents:
    Co phrase search for related documents
    • ace activation and acute respiratory distress syndrome: 1, 2, 3, 4
    • ace activity and activity post: 1, 2, 3
    • ace activity and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace activity and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • ace convert and acute respiratory: 1
    • ace expression and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace expression and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • ace homolog and acute respiratory: 1, 2, 3, 4, 5, 6, 7
    • ace homolog and acute respiratory distress syndrome: 1
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • activity post and acute respiratory: 1, 2, 3, 4, 5